Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Xyphos

    - PMLiVE

    Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell engager

    The candidate targets a tumour antigen that is highly expressed across several cancer types

    - PMLiVE

    Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment

    Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year

    - PMLiVE

    Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

    About 614,000 people are diagnosed with bladder cancer globally every year

    - PMLiVE

    Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn

    Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder

    - PMLiVE

    Astellas’ Vyloy combination approved by EC as first-line gastric cancer treatment

    Approximately 136,000 cases of the disease are diagnosed in Europe every year

    - PMLiVE

    Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval

    Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases

    - PMLiVE

    Astellas’ zolbetuximab combination receives positive CHMP opinion for advanced gastric cancer

    Gastric cancer is currently the sixth-most common cause of cancer-related mortality in Europe

    - PMLiVE

    Astellas announces EC approval of Xtandi for expanded prostate cancer use

    Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years

    - PMLiVE

    Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m

    As part of the deal, Xyphos will combine its iGPS system with Kelonia’s ACCEL technology

    - PMLiVE

    FDA publishes final industry guidance for CAR-T and gene therapies

    The new guidance can also be applied to other genetically modified lymphocyte products, including  CAR NK cells

    - PMLiVE

    Astellas’ menopause drug granted EC approval to treat vasomotor symptoms

    More than half of women aged 40 to 64 years experience symptoms such as hot flashes

    - PMLiVE

    Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant

    Vasomotor symptoms affect up to 80% of menopausal women in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links